Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura
Korean Journal of Hematology
;
: 108-112, 2009.
Artigo
em Coreano
| WPRIM
| ID: wpr-720042
ABSTRACT
Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Linfoma não Hodgkin
/
Imunoglobulinas
/
Leucemia Linfocítica Crônica de Células B
/
Vesícula
/
Síndrome de Stevens-Johnson
/
Púrpura Trombocitopênica Idiopática
/
Anticorpos Monoclonais Murinos
/
Febre
/
Rituximab
/
Coreia (Geográfico)
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Hematology
Ano de publicação:
2009
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS